← Open Payments lookup

NPI 1538749114: Open Payments

NPI 1538749114. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$494 in 17 payments from 10 companies in 2025. Trend: 2023 $1,350 · 2024 $1,546 · 2025 $494

Food & beverage: $494
CompanyPaymentsAmount
Madrigal Pharmaceuticals2$174
ABBVIE INC.4$82
Takeda Pharmaceuticals U.S.A., Inc.3$60
Salix Pharmaceuticals, a division of Bausch Health US, LLC2$47
Ipsen Biopharmaceuticals, Inc1$28
Ardelyx, Inc.1$25
Organon LLC1$23
Janssen Biotech, Inc.1$22
Gilead Sciences, Inc.1$21
Intercept Pharmaceuticals, Inc.1$14

Products named: REZDIFFRA, RINVOQ, XIFAXAN, ENTYVIO, IQIRVO, IBSRELA, HADLIMA, TREMFYA.